Digital Edition: MedTech Strategist October 2022, vol. 9 #9

article image

AI-based guidance and mapping technologies promise safer, more personalized treatments for prostate cancer. AI is impacting dermatology too: we track Pathology Watch's journey from AI developer to CLIA-certified digital path lab. Robocath is moving digital surgery from the OR into the cath lab; hospitals face major revenue declines as outpatient procedures shift offsite. Plus new solutions for blood collection, Pacertool's new biomarker for HF, and profiles of Precisis and Qnovia.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: